Bendamustine is an antineoplastic nitrogen mustard agent used in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.
- Mechanism
- Curator reviewed
Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Primary indication
- Bendamustine is indicated for use in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.Curator reviewed · 7 structured indications
- Formula / weight
- C16H21Cl2N3O2 · 358.263 g/mol (avg)
- First approval
- Canada, 2018 · United States, 2008
- Also known as
- Ribomustine
- Code names
- CEP-18083 · SDX-105
- Brand names
Resolves to
YTKUWDBFDASYHO-UHFFFAOYSA-NSMILESCN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCClWhat you can answer from here — as of October 01, 2026
Which other approved drugs treat the same conditions as Bendamustine, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account